Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer

NCT05177042 is registered in ClinicalTrials.gov with Arvinas Androgen Receptor, Inc. as lead sponsor.

NCT NCT05177042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05177042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Lead sponsor
Arvinas Androgen Receptor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 13, 2022
Completion date
April 10, 2025
Enrollment
45 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic